Industry News
Altria Sues FDA Over PMTA Delays, Demanding Overhaul of Tobacco Product Reviews
The company behind Black & Mild cigars and on! nicotine pouches is suing its own regulator. On September 2, 2026, subsidiaries of Altria Group filed a federal lawsuit against the FDA in the U.S. District Court for the Northern District of Texas, asking the court to throw out the agency's 2021 rule governing premarket tobacco product applications.
This "PMTA" system is the regulatory framework that decides which new tobacco and nicotine products may legally be sold in the United States. The lawsuit represents a direct challenge to the administrative process that has governed the industry for the last five years.
What Altria is Arguing
Under the Tobacco Control Act, the FDA is mandated to decide on a premarket application within 180 days. Altria's complaint argues the agency has never met that deadline, according to CNBC. The company alleges that the FDA improperly stops the statutory clock by running lengthy "acceptance and filing" reviews before it treats a submission as officially received. In practice, the company says, applications sit for years.
The competitive sting, in Altria's telling: while its nicotine pouches and other compliant products wait in regulatory limbo, foreign manufacturers who never filed applications at all have flooded the market and taken share. Trade press covering the suit note it is the latest in a string of industry challenges to the premarket review regime, and that even the FDA's recent moves—including a pilot program that fast-tracked some nicotine pouch reviews this year—haven't cleared the backlog.
The remedy Altria wants is blunt: vacate the 2021 PMTA rule and force the agency to rebuild its review process around the deadlines Congress wrote.
The Other Side of the Argument
Public-health groups see premarket review very differently: it exists precisely so that new nicotine products must show a net public-health benefit before reaching store shelves. Some advocates sued the FDA earlier this year, arguing the agency is already too permissive, not too slow. A court striking down the rule wouldn't automatically speed up authorizations; instead, it would create uncertainty about how new products get reviewed at all.
Furthermore, Altria is hardly a neutral party, as faster reviews would directly benefit its own product pipeline. It is also worth noting the FDA has been moving Altria's way lately, authorizing several on! and on! PLUS varieties. In August, the agency also authorized stronger ZYN Ultra pouches from rival Philip Morris under its faster pilot review.
What it Means for Shoppers
Nothing changes at the counter today. Black & Mild cigars, on!, and every currently marketed product stay exactly where they are. The stakes are about what arrives next: how quickly new pouches, cigars, and other tobacco products can legally reach shelves, and whether the gray market of never-authorized imports keeps growing while legal products wait.
If Altria wins, consumers can expect a faster (and likely more crowded) pipeline of new products. If the company loses, the status quo of multi-year reviews continues. Either way, the case will take time to move through the Northern District of Texas, and appeals are all but certain.
The Bottom Line
Altria's September 2 lawsuit turns years of industry grumbling about FDA review delays into a direct legal attack on the PMTA system itself. For the maker of Black & Mild Regular Cigars, the bet is that a Texas courtroom can do what years of lobbying couldn't: put a real clock on the FDA.